Background: Uterine cervical cancer (UCC) represents a public health problem\nin many part of the world. The use of new technologies is leading to increased\ntreatment costs, resulting in a substantial economic impact worldwide.\nStandardization of economic evaluation methods is needed to improve\ncomparisons between jurisdictions. Objective: To identify the methods used\nto measure the cost of treating invasive UCC, and to search for correlations\nbetween cancer treatment expenditures and local economies. Methods: We\nsearched articles in MEDLINE, LILACS, and SciELO with no language restrictions,\nand included publications from January 01, 2007 to December 31,\n2016. Studies were included if they described the annual direct cost of invasive\ncervical cancer and detailed the costing method. Complete economic\nevaluations were excluded. Results were described in 2016 international dollars.\nResults: Of 1581 studies initially reviewed, 13 articles were included in\nthe analysis. Six articles used a bottom-up; six used a top-down approach\nand one used both. Annual cost per patient varied from 2146.22 (Poland)\nto 34,351.54 (Sweden) International Dollars. Middle-income countries (MIC) spent median\n72.52% of its GDP per capita on the treatment of invasive cervical cancer,\nwhile high-income countries (HIC) spent median 30.12% (p = 0.032). No significant\ndifference was found when separated by costing method. Conclusions:\nWe found that, for the treatment costs of invasive UCC, the percentages\nof GDP per capita were statistically higher in MIC than in HIC. However,\nno significant difference was found between costing methods, and the\ntop-down approach could be used.
Loading....